目的:探讨健脾解毒方对氟尿嘧啶(5-Fu)治疗人胃癌细胞皮下移植瘤的增效作用.方法:采用皮下接种构建裸鼠人胃癌MKN45异位移植瘤模型,建立模型后,随机分为6组:A生理盐水组;B健脾解毒方低剂量组;C健脾解毒方中剂量组;D健脾解毒方高剂量组;E5-FU组;F健脾解毒方联合5-FU组.治疗4周后处死各组老鼠,观察健脾解毒方对移植瘤体积及裸鼠体质量的影响及对5-FU治疗效果的影响.结果:(1)对体质量的影响:经健脾解毒方及5-Fu干预后,除5-Fu组体质量增加不显著外,其余各组组间比较无统计学意义(P＞0.05).(2)对抑瘤率的影响:治疗后,健脾解毒方低、中、高剂量组、5-FU组及联合组各组的瘤体抑瘤率分别为18.96％、40.97％、50.94％、51.03％、54.43％.(3)对瘤重的影响:健脾解毒方组及5-FU组瘤体质量虽然小于模型组,但是差异无统计学差异(P＞0.05);联合给药组同模型组及低剂量组比较有统计学差异(P=0.011、P=0.032).结论:健脾解毒方煎剂具有一定抑制肿瘤生长的能力,在联合化疗药物作用下,其抑制效果明显,在有效治疗剂量中,健脾解毒方以剂量依赖性方式抑制裸鼠异位瘤的生长.

目的:评价补肾健脾法治疗慢性乙肝病毒携带者的临床疗效.方法:应用补肾健脾中药对26例慢性乙肝病毒携带者进行48周治疗,治疗前行肝穿活检,治疗期间行肝纤四项、乙肝病毒标志物定量及乙肝病毒基因型(基线)检测.结果:HBV基因型检测:B型2例,C型23例,D型1例.肝穿活检炎症分级G1(11)、G2(15),纤维化分期S0(16)、S1(10).G2级与G1级比较,HBcAb升高;S1期与S0期比较,肝纤四项无明显变化.治疗48周后HBsAg及HBeAb定量,HA降低.结论:补肾健脾中药具有一定的抗病毒及抗肝纤维化作用.

目的:探讨慢性乙肝病毒携带者不同中医证型与HBV基因型及HBV DNA载量的关系。方法:对95例慢性乙肝病毒携带者进行临床流行病学调查,组织专家组对其进行中医辨证,同时检测HBV基因型及HBV DNA载量,进行统计学分析。结果:慢性乙肝病毒携带者的中医证型以肝胃不和、肝气郁结、肝阴虚、肾阴虚证为主。4个主要证型间的HBV DNA载量比较,肝阴虚证>肝气郁结证>肝胃不和证>肾阴虚证。不同HBV基因型中HBV DNA载量比较,C型>B型。结论:不同中医证型与HBV基因型及HBV DNA载量间有一定的规律性,但无明显的相关性。

AIM:To investigate and evaluate the change in health-related quality of life (HRQoL) by tumor node metastasis (TNM) staging system in patients with hepatocellular carcinoma (HCC).METHODS:A total of 140 patients diagnosed with HCC between June 2008 and April 2009 in our department were enrolled to this study. One hundred and thirty-five (96.5%) patients had liver cirrhosis secondary to hepatitis B virus (HBV) infection, 73 (54.07%) of them being HBV DNA positive; the other etiologies of liver cirrhosis were alcoholic liver disease (1.4%), hepatitis C (1.4%) or cryptogenic (0.7%). All subjects were fully aware of their diagnosis and provided informed consent. HRQoL was assessed before treatment using the functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire. Descriptive statistics were used to evaluate demographics and disease-specific characteristics of the patients. One-way analysis of variance and independent samples t tests were used to compare the overall FACT-Hep scores and clinically distinct TNM stages. Scores for all FACT-Hep items were analyzed by frequency analyses. The mean scores obtained from the FACT-Hep in different Child-Pugh classes were also evaluated.RESULTS:The mean FACT-Hep scores were reduced significantly from TNM Stage I to Stage II, Stage IIIA, Stage IIIB group (687 ± 39.69 vs 547 ± 42.57 vs 387 ± 51.24 vs 177 ± 71.44, P = 0.001). Regarding the physical and emotional well-being subscales, scores decreased gradually from Stage I to Stage IIIB (P = 0.002 vs Stage I; P = 0.032 vs Stage II; P = 0.033 vs Stage IIIA). Mean FACT-Hep scores varied by Child-Pugh class, especially in the subscales of physical well-being, functional well-being and the hepatobiliary cancer (P = 0.001 vs Stage I; P = 0.036 vs Stage II; P = 0.032 vs Stage IIIA). For the social and family well-being subscale, only Stage IIIB scores were significantly lower as compared with Stage I scores (P = 0.035). For the subscales of functional well-being and hepatobiliary cancer, there were significant differences for Stages IIΙ, IIIA and IIIB (P = 0.002 vs Stage I).CONCLUSION:HRQoL of patients with HCC worsens gradually with progression of TNM stages. The most impaired subscales of HRQoL, as measured by FACT-Hep, were physical and emotional well-being.

Objective:To explore the distributive regularity of TCM syndromes of chronic HBV carriers.Methods:Organize experts to make clinical epidemiology survey,analyse the TCM syndromes and conduct the statistics frequency of TCM syndromes to the chronic HBV carriers.Results:The main syndrome types were Disharmony betueen liver and stomach syndrome,Liver-qi stagnation syndrome,Deficiency of liver-yin syndrome,Deficiency of kidney-yin syndrome.Conclusion:The distribution of TCM syndromes of chronic HBV carriers was regular.

OBJECTIVE: To investigate the application of Traditional Chinese Medicine Injections (TCMIs) for treatment of primary liver cancer (PLC).METHODS: A literature review was conducted using PubMed/Medline, Cochrane Library Controlled Clinical Trials Database, China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (CSJD) and China Biology Medicine (CBM). Online websites including journal websites and databases of ongoing trials, as well as some Traditional Chinese Medicine journals that are not indexed in the electronic databases were also searched.RESULTS: The literature review showed that TCMIs as adjunctive medication for the treatment of PLC could regulate patient immunity, reduce bone marrow suppression, relieve clinical symptoms, and improve quality of life, as well as control disease progression and prolong survival time.CONCLUSION: Within the limitations of this review, we conclude that application of TCMIs as adjunctive medication may provide benefits for patients with PLC. Further large, high-quality trials are warranted. (C) 2012 JTCM. All rights reserved.